Accreditation

0.75 AMA PRA Category 1 Credit(s)™.
Read the full Accreditation Statement

Target Audience

Directed to gastroenterologists, infectious disease physicians, infectious disease and gastroenterology nurse practitioners, infection control nurses, physician assistants, and managed care organizations.

Description

The Hepatitis C Management Series includes interactive cases, corresponding to the Hepatitis C Management Monograph.

Throughout the interactive case, you may proceed to the next question once you answer each question correctly. In addition to allowing you to proceed, the correct answer also reveals the rationale for the answer.

Upon completing the CME activity, the evaluation and registration forms, you will have the opportunity to print a CME certificate. 

Objectives

At the conclusion of this activity, the participant will be able to:

1. Explain the aggressive nature of hepatitis C virus (HCV) recurrence after liver transplantation.
2. Recognize post-liver transplant intervention that may worsen the natural history of HCV recurrence.
3. Identify histologic features of HCV recurrence after liver transplantation, as well as overlapping features with allograft rejection.
4. Discuss hematologic toxicity of anti-HCV therapy in liver transplant recipients.
5. Discuss "standard" and "extended" goals of anti-HCV therapy in liver transplant recipients.

Activity Director

William D. Carey, MD
Department of Gastroenterology & Hepatology
The Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Author

Marcelo Kugelmas, MD

Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he does have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:

Marcelo Kugelmas, MD
      — Grant/Research Support: Schering-Plough, Amgen
      — Consultant: Schering-Plough
      — Speakers' Bureau: GlaxoSmithKline, Gilead, Amgen, Schering-Plough